What changed
$AZN — BUY 📊 | 6 MONTHS THESIS
🎯 latest | Rev $2.7B | EPS $1.29 vs $1.27 🟢
💡 Consensus expected modest EPS of $1.27, reflecting concerns over patent expirations and competitive pressure. The beat to $1.29, while small, highlights ongoing revenue growth from key drugs (e.g., Tagrisso, Imfinzi) that is not fully reflected in analyst models or the current elevated P/E, which discounts pipeline success.
📉 Reward/risk: 2.73:1
🏢 Business Quality: 9/10 - Industry-leading oncology portfolio, diversified biopharma assets, and strong R&D productivity, though offset by near-term patent cliffs.
📊 Valuation: rich - Trades at 34.6x annualized EPS, well above Pharma peers (18-22x) and historical averages. EV/EBITDA ~16x vs peers ~14x.
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/AZN0614